Enzymatic wound debriding compositions with enhanced enzymatic activity

Patent metadata

Field	Value
Publication number	US-10155061-B2
Application number	US-201615358937-A
Country	US
Kind code	B2
Filing date	Nov 22, 2016
Priority date	Dec 8, 2009
Publication date	Dec 18, 2018
Grant date	Dec 18, 2018

Abstract

The present invention is directed to topical enzymatic wound debriding compositions with enhanced enzymatic activity. These compositions comprise a dispersed phase comprising at least one proteolytic enzyme and at least one hydrophilic polyol; and a continuous phase comprising a hydrophobic base.

First claim

The invention claimed is:

1. An enzymatic wound debriding composition comprising:
(a) a hydrophobic dispersed phase comprising an amount of PEG 400 providing the maximum enzymatic activity of the composition, and thermolysin; and
(b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase,
wherein the amount of PEG 400 is from 19-39% w/w of the composition,
wherein the composition is anhydrous, and
wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, paraffin, and combinations thereof.

2. The enzymatic wound debriding composition of claim 1 , wherein the hydrophobic base is petrolatum.

3. The enzymatic wound debriding composition of claim 1 , wherein the amount of PEG 400 is from 22-36% w/w of the composition.

4. The enzymatic wound debriding composition of claim 1 , wherein the amount of PEG 400 is 29% w/w of the composition.

5. The enzymatic wound debriding composition of claim 1 , wherein the composition is a liquid.

6. The enzymatic wound debriding composition of claim 1 , wherein the composition is a semi-solid.

7. The enzymatic wound debriding composition of claim 1 , wherein the composition is sterile.

8. A method of debriding a wound in need of debridement, the method comprising applying to the wound an effective amount of an anhydrous enzymatic composition to debride the wound, the anhydrous enzymatic composition comprising:
a) a hydrophobic dispersed phase comprising an amount of PEG 400 providing the maximum enzymatic activity of the composition, and thermolysin; and
(b) a hydrophobic continuous phase comprising a hydrophobic base, wherein the hydrophilic dispersed phase is dispersed in the hydrophobic continuous phase,
wherein the amount of PEG 400 is from 19-39% w/w of the composition, and
wherein said hydrophobic base is selected from the group consisting of isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, petrolatum, paraffin, and combinations thereof.

9. The method of claim 8 , wherein the hydrophobic base is petrolatum.

10. The method of claim 8 , wherein the amount of PEG 400 is from 22-36% w/w of the composition.

11. The method of claim 8 , wherein the amount of PEG 400 is 29% w/w of the composition.

12. The method of claim 8 , wherein the composition is a liquid.

13. The method of claim 8 , wherein the composition is a semi-solid.

14. The method of claim 8 , wherein the composition is sterile.

Assignees

• Smith & Nephew Inc

Inventors

• Shi Lei
• Jovanovic Aleksa
• Aust Duncan

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P17/02

  for treating wounds, ulcers, burns, scars, keloids, or the like · CPC title

• A61L15/34

  Oils, fats, waxes or natural resins {(A61L15/225 takes precedence)} · CPC title

• A61K38/488

  Aspartic endopeptidases (3.4.23), e.g. pepsin, chymosin, renin, cathepsin E · CPC title

• A61L2300/254

  Enzymes, proenzymes · CPC title